609-537-6363

609-537-6363

Cancer Research at Capital Health

Our Clinical Cancer Trials

Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.

Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.

Our experienced oncologists and clinical research staff carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study.

Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.

The National Cancer Institute has a brochure “Taking Part in Cancer Treatment Research Studies” to help you understand the details of clinical trials (https://www.cancer.gov/publications/patient-education/cancer-treatment-research-studies).

To learn more about our ongoing trials for cancer treatment and prevention, please contact Tina Bergner, RN, BSN, OCN, oncology clinical research coordinator, at 609-537-7042 or e-mail her at tbergner@capitalhealth.org for more information.

Active Clinical Trials Currently Offered:

Brain Studies

3D-PREDICT REGISTRY: 3D Prediction of patient-specific response using ex vivo interrogation of live cells from tumors

  • Study Information: NCT03561207 (https://clinicaltrials.gov/ct2/show/NCT03561207)
  • Sponsor: KIYATEC, Inc.
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact:  Office of Clinical Research at 609-394-4130

 

Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery

  • Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

Molecular and biochemical characterization of malignant and metastatic brain tumors

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with Princeton University and Rutgers University
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

Genomically-guided treatment trial in brain metastasis

  • Study Information: NCT03994796, NCTN# A071701 (https://clinicaltrials.gov/ct2/show/NCT03994796)
  • Sponsor: Alliance for Clinical Trials
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Dr. Neel Gandhi, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

 

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma With Elevated Mutational Burden

  • Study Information: NCT04145115; NCTN # A071702 (https://clinicaltrials.gov/ct2/show/NCT04145115)
  • Sponsor: Alliance in Clinical Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

Testing the Use of the Immunotherapy Drugs, Ipilimumab and Nivolumab, Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  • Study Information: NCT04396860; NCTN # NRG BN007 (https://clinicaltrials.gov/ct2/show/NCT04396860)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Neel Gandhi, MD, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

 

Assessing quality of life in adult neuro-oncology patients after Cyberknife or WBRT (Whole Brain Radiation Therapy), a prospective registry

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

 

The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Liver and Pancreas Studies

Registry to evaluate effectiveness and safety of the Nanoknife system for the ablation of stage 3 pancreatic cancer – DIRECT

  • Study Information: NCT03899649 (https://clinicaltrials.gov/ct2/show/NCT03899649)
  • Sponsor: Angiodynamics, Inc.
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Circulating Biomarkers and Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Gynecological Studies

A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers

  • Study Information: NCT04251052, NCTN# CC008 (https://clinicaltrials.gov/ct2/show/NCT04251052)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Joyce Varughese, MD, FACOG, Gynecologic Oncology Surgeon
  • Contact: Office of Clinical Research at 609-394-4130

Lung Studies

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer” with Protocol number M14-239

  • Principal Investigator: Dr. Scott Kindsfather, Hematologic and Oncologic Diseases
  • Sub-Investigator: Dr. Africa Wallace, Thoracic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

A randomized phase III trial of induction/consolidation Atezolizumab + SBRT Versus SBRT alone in high risk, early stage NSCLC

  • Study Information: NCT0421462, NCTN #S1914 (https://clinicaltrials.gov/ct2/show/NCT04214262)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer

  • Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • Study Information: NCT04402788; NCTN #NRG-LU007 (https://clinicaltrials.gov/ct2/show/NCT04402788)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

  • Study Information: NCT03811002; NCTN #NRG-LU005 (https://clinicaltrials.gov/ct2/show/NCT03811002)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Gastro-Intestinal Studies

A randomized trial of the altering intake, managing symptoms interventions for bowel dysfunction in rectal cancer survivors compared to a healthy living education control: A feasibility and preliminary efficacy study (AIMS-RC) S1820

Bespoke Study of ctDNA Guided Therapy in Colorectal Cancer

  • Study Information: NCT04264702 (https://clinicaltrials.gov/ct2/show/NCT04264702)
  • Sponsor: NATERA
  • Principal investigator: Dr. Ashlee Godshalk-Ruggles, Colo-Rectal Surgery
  • Sub-Investigator: Dr. Hongyan Liang, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

Other Studies

NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma

  • Study Information: NCT02465060, NCTN# EAY131 (https://clinicaltrials.gov/ct2/show/NCT02465060)
  • Sponsor: National Cancer Institute (NCI)
  • Principal Investigator: David Schaebler, MD, Medical Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Cancer Tissue Biorepository

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Office of Clinical Research at 609-394-4130

Urogenital Studies

Diagnostic Markers in Patients with Bladder Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Eric Mayer, MD, Urologic Oncology Surgeon, Director, Urologic Robotic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

Stereotactic Body Radiation Therapy or Intesity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer

  • Study Information: NCT03367702; NCTN #NRG-GU005 (https://clinicaltrials.gov/ct2/show/NCT03367702)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Timothy Chen, MD, Radiation Oncologist, Medical Director, Stereotactic Radiosurgery
  • Contact: Office of Clinical Research at 609-394-4130

Other resources:

Brain Studies

  • Study Information: NCT03561207 
    (https://clinicaltrials.gov/ct2/show/NCT03561207)
  • Sponsor: KIYATEC, Inc.
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact:  Office of Clinical Research at 609-394-4130

  • Study Information: NCT03180268, NCTN# NRG BN003 (https://clinicaltrials.gov/ct2/show/NCT03180268)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with Princeton University and Rutgers University
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT03994796, NCTN# A071701 (https://clinicaltrials.gov/ct2/show/NCT03994796)
  • Sponsor: Alliance for Clinical Trials
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Dr. Neel Gandhi, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130
  •  

  • Study Information: NCT04145115; NCTN # A071702 (https://clinicaltrials.gov/ct2/show/NCT04145115)
  • Sponsor: Alliance in Clinical Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT04396860; NCTN # NRG BN007 (https://clinicaltrials.gov/ct2/show/NCT04396860)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Neel Gandhi, MD, Medical Director, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130
  •  

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Office of Clinical Research at 609-394-4130

Liver and Pancreas Studies

  • Study Information: NCT03899649 (https://clinicaltrials.gov/ct2/show/NCT03899649)
  • Sponsor: Angiodynamics, Inc.
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Office of Clinical Research at 609-394-4130

Gynecological Studies

  • Study Information: NCT04251052, NCTN# CC008 (https://clinicaltrials.gov/ct2/show/NCT04251052)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Joyce Varughese, MD, FACOG, Gynecologic Oncology Surgeon
  • Contact: Office of Clinical Research at 609-394-4130

Lung Studies

  • Principal Investigator: Dr. Scott Kindsfather, Hematologic and Oncologic Diseases
  • Sub-Investigator: Dr. Africa Wallace, Thoracic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT0421462, NCTN #S1914 (https://clinicaltrials.gov/ct2/show/NCT04214262)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT04402788; NCTN #NRG-LU007 (https://clinicaltrials.gov/ct2/show/NCT04402788)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT03811002; NCTN #NRG-LU005 (https://clinicaltrials.gov/ct2/show/NCT03811002)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Khanh Nguyen, MD, MA, Radiation Oncologist
  • Contact: Office of Clinical Research at 609-394-4130

Gastro-Intestinal Studies

  • Study Information: NCT04264702 (https://clinicaltrials.gov/ct2/show/NCT04264702)
  • Sponsor: NATERA
  • Principal investigator: Dr. Ashlee Godshalk-Ruggles, Colo-Rectal Surgery
  • Sub-Investigator: Dr. Hongyan Liang, Hematologic and Oncologic Diseases
  • Contact: Office of Clinical Research at 609-394-4130

Other Studies

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Office of Clinical Research at 609-394-4130

Urogenital Studies

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Eric Mayer, MD, Urologic Oncology Surgeon, Director, Urologic Robotic Surgery
  • Contact: Office of Clinical Research at 609-394-4130

  • Study Information: NCT03367702; NCTN #NRG-GU005 (https://clinicaltrials.gov/ct2/show/NCT03367702)
  • Sponsor: NRG Oncology
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Timothy Chen, MD, Radiation Oncologist, Medical Director, Stereotactic Radiosurgery
  • Contact: Office of Clinical Research at 609-394-4130

Other resources:

Font Resize